Patient’s Corner: Elizabeth Stephenson, a survivor of lung cancer, explains how she fears her cancer recurring, but she also fears losing the ability to pay for her #CancerCosts due to possible federal cuts to the Affordable Care Act 👉 https://t.co/CDqXXX3x3E

Why do some patients with #MultipleMyeloma stay in remission >5 years after #CARTcell? @IcahnMountSinai study points to host immunity differentiators. Findings may shape future biomarkers & strategies. Senior author: Alessandro Laganà, PhD 🔗 https://t.co/BEgHbHgE5q

Experts from @ASTRO_org commented on results of SUPREMO trial on post-mastectomy RT for pts with early #BreastCancer: 🔸Patients treated 2006–2013 🔸Approaches differed from current practice 🔸Findings shouldn’t change how most patients treated today 🔗 https://t.co/LitFI2T7vA

The November 25 issue of The ASCO Post features insights from #ESMO25, #ASTRO25, #NCCNhem25; perspectives on the #AI era changing health care, cancer survivor concerns of health care costs, and MORE. Read the full issue 👉 https://t.co/D3cDx8SXZj

#FDAApproval: The @US_FDA has approved durvalumab (Imfinzi) in combination with FLOT chemotherapy as neoadjuvant/adjuvant treatment, followed by single-agent durvalumab, for adults with resectable gastric/GEJ adenocarcinoma #GastricCancer https://t.co/JaYa5N8I21

🆕A new study identifies a #melanoma cancer cluster across 15 Pennsylvania counties, linked to herbicide use on cultivated croplands. Findings suggest environmental exposure may raise risks even for non-farmers. Senior author: @EugeneLengerich 🔗 https://t.co/bwOcDdNKVc

#FDAApproval: The @US_FDA has approved pembrolizumab (Keytruda/Keytruda Qlex) with enfortumab vedotin-ejfv (Padcev) as neoadjuvant therapy followed by cystectomy & adjuvant therapy for adults with MIBC who are ineligible for cisplatin #BladderCancer https://t.co/mrQ7OxgPi9

Catch up on all of the highlights from ESMO Congress 2025! Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers. 🔗 https://t.co/uHgq1sLb78

SUPREMO 10-yr findings: Postmastectomy chest-wall irradiation showed no significant difference in 10-year overall survival in intermediate-risk early breast cancer. Local recurrence was lower, but DFS was similar #BCSM 🔸Ian H. Kunkler, FRCR @EdinUni_IGC 🔗 https://t.co/LXNv1m07l4

🧬 Chinese phase III BL-B01D1-303 trial: Izalontamab brengitecan (EGFR×HER3 ADC) doubled ORR vs chemo (54.6% vs 27%) in heavily pretreated #nasopharyngeal carcinoma 📊 PFS 8.4 vs 4.3 mo 🌟 Potential new SOC, says Yang et al in @TheLancet 🔗 https://t.co/lsH0VKmjLW

🆕 @AmericanCancer data: Structured support for patients—transportation help, reminders, navigators—reduced missed radiation visits by nearly 40% across 90k+ patients. ☑️ A major step toward improving treatment completion 👩‍⚕️ Laurie Kirstein, MD, FACS 🔗 https://t.co/8DSlv7Vw7s

🫁 OptiTROP-Lung04 phase III: Sacituzumab tirumotecan significantly improved PFS (8.3 vs 4.3 mo; HR = 0.49) & OS vs platinum chemo in EGFR+ #NSCLC after TKI failure #LCSM 🩺No ILD/pneumonitis, fewer TRAEs 👨‍⚕️Presenter Li Zhang, MD; Discussant @APassaroMD 🔗 https://t.co/vUVgoiVOxF

🆕 @americancancer study shows patients with cancer increasingly turn to crowdfunding for medical, living expenses. Only 11.5% of campaigns meet their goals, revealing major gaps in affordability and financial assistance #CostsofCare 🔸Zhiyuan Zheng, PhD 🔗 https://t.co/IGlUX49Ing

🔬Routine liquid biopsy screening for multiple cancers could cut late-stage cancer diagnoses nearly in half, per new modeling data of 14 cancer types. Earlier detection may significantly improve outcomes and reduce disease burden. 🔷 @JagChhatwal et al 🔗 https://t.co/BiC7O0k2km

🆕 @IARCWHO-led study shows regular pharmaceutical #opioid use may raise risks for opium-related cancers; stronger, longer-acting opioids linked to higher risk. Authors @mahdi_iarc et al urge for more research to clarify clinical relevance #opioidcrisis 🔗 https://t.co/1q8BPNAhVH

🔬 MAST phase III trial: Metformin did not improve PFS vs placebo in men on active surveillance for low-risk #ProstateCancer. ⚖️ Similar 3-year outcomes; HR = 1.09 📈 Possible increased progression risk in obese patients ✍️ @FleshnerNeil et al 🔗 https://t.co/Flrx4LRiA5

#FDAApproval: The @US_FDA has granted a traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer #SCLC with disease progression on/after platinum-based chemotherapy 🔗 https://t.co/hklL29MfBb

DeFi trial long-term update @JCO_ASCO: Continuous nirogacestat showed durable benefit in adults with desmoid tumors 📊 ORR rose to 44% by 3 yrs; tumor shrinkage deepened over time 🧬 PRO gains sustained; AEs decreased over time 🔷 Ravin Ratan, MD, MEd 🔗 https://t.co/76BX5r9GLg

#FDAApproval: The @US_FDA has granted an accelerated approval to the kinase inhibitor sevabertinib (Hyrnuo) for adults with locally advanced/metastatic nonsquamous #NSCLC with HER2-TKD activating mutations, and have received a prior systemic therapy #LCSM https://t.co/ExlaSOUbta

Surveyed patients with advanced #bloodcancers ranked transfusion access as the most important factor in hospice decision-making. Integrating #palliative transfusions into hospice models urgently needed to improve end-of-life care. 🔷@OdejideOreofe 🔗 https://t.co/N4Dx0jjr7W